Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.

Pai SI, Jack Lee J, Carey TE, Westra WH, Ferrone S, Moore C, Mosunjac MB, Shin DM, Ferris RL; HNC SPORE HIV supplement consortium.

Oral Oncol. 2018 Feb;77:92-97. doi: 10.1016/j.oraloncology.2017.12.014. Epub 2017 Dec 28.

2.

SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells.

Leibowitz MS, Srivastava RM, Andrade Filho PA, Egloff AM, Wang L, Seethala RR, Ferrone S, Ferris RL.

Clin Cancer Res. 2013 Feb 15;19(4):798-808. doi: 10.1158/1078-0432.CCR-12-1517. Epub 2013 Jan 30.

3.

Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells.

Concha-Benavente F, Srivastava R, Ferrone S, Ferris RL.

Oral Oncol. 2016 Jul;58:52-8. doi: 10.1016/j.oraloncology.2016.05.008. Epub 2016 Jun 2. Review.

4.

Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.

Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, Seliger B.

Clin Cancer Res. 2005 Apr 1;11(7):2552-60.

5.

Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.

Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wullich B, Tannapfel A, Hofstaedter F, Hartmann A.

Cancer Immunol Immunother. 2010 Apr;59(4):529-40. doi: 10.1007/s00262-009-0769-5. Epub 2009 Oct 7.

6.

STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.

Srivastava RM, Trivedi S, Concha-Benavente F, Hyun-Bae J, Wang L, Seethala RR, Branstetter BF 4th, Ferrone S, Ferris RL.

Cancer Immunol Res. 2015 Aug;3(8):936-45. doi: 10.1158/2326-6066.CIR-15-0053. Epub 2015 May 13.

7.

Post-transcriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur women.

Hasim A, Abudula M, Aimiduo R, Ma JQ, Jiao Z, Akula G, Wang T, Abudula A.

PLoS One. 2012;7(9):e44952. Epub 2012 Sep 14.

8.

PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.

Sabbatino F, Villani V, Yearley JH, Deshpande V, Cai L, Konstantinidis IT, Moon C, Nota S, Wang Y, Al-Sukaini A, Zhu AX, Goyal L, Ting DT, Bardeesy N, Hong TS, Fernandez-del Castillo C, Tanabe KK, Lillemoe KD, Ferrone S, Ferrone CR.

Clin Cancer Res. 2016 Jan 15;22(2):470-8. doi: 10.1158/1078-0432.CCR-15-0715. Epub 2015 Sep 15.

9.

The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.

Imai D, Yoshizumi T, Okano S, Uchiyama H, Ikegami T, Harimoto N, Itoh S, Soejima Y, Aishima S, Oda Y, Maehara Y.

Cancer Med. 2017 Jul;6(7):1614-1626. doi: 10.1002/cam4.1087. Epub 2017 Jun 10.

10.

Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.

Yanik EL, Kaunitz GJ, Cottrell TR, Succaria F, McMiller TL, Ascierto ML, Esandrio J, Xu H, Ogurtsova A, Cornish T, Lipson EJ, Topalian SL, Engels EA, Taube JM.

JAMA Oncol. 2017 Jul 1;3(7):974-978. doi: 10.1001/jamaoncol.2017.0115.

11.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

12.

Evolution of studies of HLA class I antigen processing machinery (APM) components in malignant cells.

Sabbatino F, Schwab JH, Ferrone S, Ferrone CR.

Clin Transpl. 2013:453-63. Review.

PMID:
25095541
13.

Defective HLA class I antigen processing machinery in cancer.

Cai L, Michelakos T, Yamada T, Fan S, Wang X, Schwab JH, Ferrone CR, Ferrone S.

Cancer Immunol Immunother. 2018 Jun;67(6):999-1009. doi: 10.1007/s00262-018-2131-2. Epub 2018 Feb 27.

PMID:
29487978
15.

Down-regulation of HLA class I antigen-processing machinery components in esophageal squamous cell carcinomas: association with disease progression.

Liu Q, Hao C, Su P, Shi J.

Scand J Gastroenterol. 2009;44(8):960-9. doi: 10.1080/00365520902998679.

PMID:
19492245
16.

Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma.

Raffaghello L, Nozza P, Morandi F, Camoriano M, Wang X, Garrè ML, Cama A, Basso G, Ferrone S, Gambini C, Pistoia V.

Cancer Res. 2007 Jun 1;67(11):5471-8.

18.

Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors.

Facoetti A, Nano R, Zelini P, Morbini P, Benericetti E, Ceroni M, Campoli M, Ferrone S.

Clin Cancer Res. 2005 Dec 1;11(23):8304-11.

19.

Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?

Atkins D, Ferrone S, Schmahl GE, Störkel S, Seliger B.

J Urol. 2004 Feb;171(2 Pt 1):885-9.

PMID:
14713847
20.

HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape.

Perea F, Sánchez-Palencia A, Gómez-Morales M, Bernal M, Concha Á, García MM, González-Ramírez AR, Kerick M, Martin J, Garrido F, Ruiz-Cabello F, Aptsiauri N.

Oncotarget. 2017 Dec 19;9(3):4120-4133. doi: 10.18632/oncotarget.23469. eCollection 2018 Jan 9.

Supplemental Content

Support Center